Publication | Closed Access

Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis

InflammationNanomedicineChronic Inflammatory DiseasesAnti-inflammatoryEngineeringMucosal ImmunologyImmunologyDysregulated Intestinal BarrierDrug Delivery SystemsHyaluronic Acid–bilirubin NanomedicineBiomedical EngineeringTargeted ModulationGut BarrierMedicine